09:07 AM EST, 01/26/2026 (MT Newswires) -- Sarepta Therapeutics ( SRPT ) said Monday that three-year results from part 1 of a phase 3 EMBARK study of its gene therapy, Elevidys, in ambulatory patients with Duchenne muscular dystrophy showed continued benefit.

The company said patients who received the therapy showed statistically significant efficacy on key motor function tests three years after treatment compared with an untreated control group.

The study also showed that the therapy slowed disease progression by 70% to 73% over three years, the company added.